PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-India resumes coronavirus vaccine exports to COVAX

Fri, 26th Nov 2021 11:50

(Adds details, COVAX comment)

BENGALURU, Nov 26 (Reuters) - India restarted exports of
COVID-19 shots to the global vaccine-sharing network COVAX on
Friday for the first time since April, and producer Serum
Institute of India (SII) forecast a substantial increase in
supplies from early next year.

The resumption came as a new coronavirus variant https://www.reuters.com/business/healthcare-pharmaceuticals/japan-tighten-border-controls-s-africa-others-new-virus-variant-jiji-2021-11-26
detected in South Africa spooked the world and prompted some
new travel curbs.

SII, the world's biggest vaccine maker, said https://www.seruminstitute.com/press_release_sii_261121.php
it was able to recommence exports because it had beaten its
target of producing 1 billion doses of the AstraZeneca
vaccine ahead of time.

Much of that output has been used in India, which stopped
exports eight months ago to inoculate its own people when
infections surged.

SII has a deal to supply up to 550 million doses of the shot
to COVAX, which mainly provides doses to low-income countries.
So far, COVAX has received only about 30 million from SII.

SII's output of the vaccine, which it calls Covishield, has
nearly quadrupled to as many as 240 million doses a month since
the halt in exports.

"SII's supply of doses via COVAX is expected to increase
substantially into Quarter 1, 2022," it said.

A spokesperson from GAVI, which runs the COVAX program along
with the World Health Organization, said that volumes delivered
would increase rapidly with the export resumption, but did not
give any numbers.

SII said it had already produced more than 1.25 billion
Covishield doses and was now working on expanding the output of
other shots, including its licensed version of the Novavax
vaccine.

The company did not say on Friday how many doses it was
shipping to COVAX. A government official told Reuters last week
that Covishield exports to the global platform may not exceed 10
million doses for the rest of the year.
(Reporting by Shivani Singh and Chris Thomas in Bengaluru and
Krishna N. Das in New Delhi
Editing by Shounak Dasgupta, Aditya Soni and Frances Kerry)

More News
16 May 2024 10:27

AstraZeneca trials yield positive results for immunocompromised patients

(Alliance News) - AstraZeneca PLC on Thursday said results from recent trials revealed a significant reduction in cases of Covid-19.

Read more
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.